Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells. - Zaffran I; Landolina N; Gaur P; Rovis TL; Jonjic S; Mandelboim O; Singer BB; Levi-Schaffer F (Cancer gene therapy, 2022)